{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-24-000033","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.997365+00:00","generated_at":"2026-06-04T15:16:44.117038+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Arvinas appoints Noah Berkowitz as Chief Medical Officer, replacing Ron Peck","bullets":["Noah Berkowitz, M.D., Ph.D., appointed CMO effective March 18, 2024, succeeding Ron Peck, M.D.","Berkowitz brings 20+ years of experience, most recently as SVP at Bristol-Myers Squibb in hematology.","He will lead clinical development of Arvinas' PROTAC protein degrader programs in oncology and neuroscience.","Former CMO Ron Peck to remain an employee until mid-April 2024 for transition, then eligible for severance."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-24-000033","json":"https://secwatch.observer/filing/0001655759-24-000033.json","markdown":"https://secwatch.observer/filing/0001655759-24-000033.md","text":"https://secwatch.observer/filing/0001655759-24-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000033/0001655759-24-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000033/arvn-20240314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T15:16:44.117038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"010376a9a0","claim":"Noah Berkowitz was appointed as chief medical officer at ARVINAS, INC..","evidence_excerpt":"On March 18, 2024, Arvinas, Inc., a Delaware corporation (the “Company”), announced the appointment of Noah Berkowitz, M.D., Ph.D., to the role of chief medical officer, effective as of March 18, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000033/0001655759-24-000033-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"chief medical officer"}],"fact_type":"executive_change"},{"claim_id":"1dd21e8141","claim":"Ron Peck departed as chief medical officer at ARVINAS, INC..","evidence_excerpt":"On March 14, 2024, the Company notified Ron Peck, M.D., the Company’s previously serving chief medical officer, of Dr. Berkowitz’s pending appointment and the reassignment of the responsibilities of chief medical officer to Dr. Berkowitz effective as of March 18, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000033/0001655759-24-000033-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"chief medical officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}